Evidence map›Paper›PMID 34054173›Full record

ArticleMedicina intensiva

Histopathological features in fatal COVID-19 acute respiratory distress syndrome.

H Merdji, S Mayeur, M Schenck, W Oulehri, R Clere-Jehl, S Cunat, J-E Herbrecht, R Janssen-Langenstein, A Nicolae, J Helms and 3 more

Open access · greenAbstract read
In one paragraph

Article in Medicina intensiva. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.6field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 28 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Time-Dependent Molecular Motifs of Pulmonary Fibrogenesis in COVID-19.International journal of molecular sciences · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

H MerdjiService de Médecine Intensive - Réanimation, Nouvel Hôpital Civil, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.
S MayeurDépartement de Pathologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.
M SchenckService de Médecine Intensive - Réanimation, Hautepierre, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.
W OulehriService d'Anesthésie - Réanimation Chirurgicale, Nouvel Hôpital Civil, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.
R Clere-JehlService de Médecine Intensive - Réanimation, Nouvel Hôpital Civil, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.
S CunatService de Médecine Intensive - Réanimation, Nouvel Hôpital Civil, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.
J-E HerbrechtService de Médecine Intensive - Réanimation, Hautepierre, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.
R Janssen-LangensteinService de Médecine Intensive - Réanimation, Hautepierre, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.
A NicolaeDépartement de Pathologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.
J HelmsService de Médecine Intensive - Réanimation, Nouvel Hôpital Civil, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.
F MezianiService de Médecine Intensive - Réanimation, Nouvel Hôpital Civil, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.
M-P ChenardDépartement de Pathologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.
CRICS TRIGGERSEP Group (Clinical Research in Intensive Care, Sepsis Trial Group for Global Evaluation, Research in Sepsis)
Hôpitaux Universitaires de Strasbourg · FRRegenerative NanoMedicine · FRFédération Hospitalo-Universitaire, Paris Center for Microbiome Medicine · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: COVID-19 acute respiratory distress syndrome (ARDS) shares the common histological hallmarks with other forms of ARDS. However, the chronology of the histological lesions has not been well established. Objective: To describe the chronological histopathological alterations in the lungs of patients with COVID-19 related ARDS. Design: A prospective cohort study was carried out. Setting: Intensive Care Unit of a tertiary hospital. Patients: The first 22 consecutive COVID-19 deaths. Measurements: Lung biopsies and histopathological analyses were performed in deceased patients with COVID-19 related ARDS. Clinical data and patient course were evaluated. Results: The median patient age was 66 [63-74] years; 73% were males. The median duration of mechanical ventilation was 17 [8-24] days. COVID-19 induced pulmonary injury was characterized by an exudative phase in the first week of the disease, followed by a proliferative/organizing phase in the second and third weeks, and finally an end-stage fibrosis phase after the third week. Viral RNA and proteins were detected in pneumocytes and macrophages in a very early stage of the disease, and were no longer detected after the second week. Limitation: Limited sample size. Conclusions: The chronological evolution of COVID-19 lung histopathological lesions seems to be similar to that seen in other forms of ARDS. In particular, lung lesions consistent with potentially corticosteroid-sensitive lesions are seen.

Indexed as

ACE2, angiotensin-converting enzyme 2AFOP, acute fibrinous and organizing pneumoniaARDS, acute respiratory distress syndromeCOVID-19COVID-19, coronavirus infectious diseaseCOVID-19 related acute respiratory distress syndromeDAD, diffuse alveolar damageHE, hematoxylin–eosinHistopathologyISH, in situ hybridizationNMBD, neuromuscular blocking drugsRT-PCR, Reverse Transcriptase-Polymerase chain reactionSAPSII, simplified acute physiology scoreSARS-CoV-2SOFA, Sequential Organ Failure AssessmentVILI, ventilator induced lung injury

Identifiers

PMID34054173
PMCPMC7914021
OpenAlexW3135555115

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.